Simon E. Hufton

Section Head

Simon E. Hufton, PhD joined NIBSC (Potters Bar, UK) in 2009 and his interests include antibody immunotherapy and protein structure-function particularly related to the efficacy, quality and safety of biological medicines. He has over 20 years’ experience in the therapeutic monoclonal antibody field including as Director of Research at Dyax

Corp (Liege, Belgium) and Wyeth (Dublin Ireland). He is a biochemist by training and has authored over 30 publications on various aspects of monoclonal antibodies.

International Standards to Support the Consistency of Therapeutic Monoclonal Antibodies Bioactivity Over Time: Evidence from an International Collaborative Study for Rituximab
Wednesday, July 18, 2018

Subscriptions

Get started here for your complimentary print or digital subscription

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Simon E. Hufton

Articles by Simon E. Hufton

International Standards to Support the Consistency of Therapeutic Monoclonal Antibodies Bioactivity Over Time: Evidence from an International Collaborative Study for Rituximab

Subscriptions

Connect with Us

Subscribe to eNewsletters